NEWS
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
Organovo Holdings (Nasdaq: ONVO) presented its outlook and plans at the Jones Trading Healthcare Conference, focusing on FXR314, its treatment for inflammatory bowel disease (IBD). Executive Chairman Keith Murphy highlighted the strong preclinical and human rationale for FXR314 in Phase 2a ulcerative colitis trials. The company aims to demonstrate FXR314's activitymatching results from predictive animal models and 3D human models of ulcerative colitis and Crohn's disease. Murphy emphasized the importance of swift trial completion for investors and patients, noting the strong M&A activity in IBD, referencing Lilly's $3.2B acquisition of Morphic following positive Phase 2a results. The presentation webcast is available for viewing on the Jones Trading website.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1826Followers
98Following
15KVisitors
Follow